NASDAQ:CRSP - Crispr Therapeutics Stock Price, Forecast & News

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Crispr Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings results on Monday, October, 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. View Crispr Therapeutics' Earnings History.

Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Crispr Therapeutics.

14 brokers have issued twelve-month price objectives for Crispr Therapeutics' stock. Their forecasts range from $21.00 to $104.00. On average, they expect Crispr Therapeutics' share price to reach $72.86 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics.

Headlines about CRSP stock have been trending very positive on Saturday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crispr Therapeutics earned a news sentiment score of 3.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Crispr Therapeutics.

Crispr Therapeutics saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 3,400,000 shares, a decline of 6.1% from the November 28th total of 3,620,000 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is currently 3.4 days. Approximately 9.9% of the shares of the stock are sold short. View Crispr Therapeutics' Current Options Chain.

Some companies that are related to Crispr Therapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA) and Acceleron Pharma (XLRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Canopy Growth (CGC), Shopify (SHOP), Advanced Micro Devices (AMD), Netflix (NFLX) and Tesla (TSLA).

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Crispr Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ipswich Investment Management Co. Inc. (0.08%), Perigon Wealth Management LLC (0.01%), Webster Bank N. A. (0.00%) and Farmers & Merchants Trust Co of Chambersburg PA (0.00%). Company insiders that own Crispr Therapeutics stock include Bradley J Phd Bolzon, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View Institutional Ownership Trends for Crispr Therapeutics.

CRSP stock was sold by a variety of institutional investors in the last quarter, including Ipswich Investment Management Co. Inc.. Company insiders that have sold Crispr Therapeutics company stock in the last year include Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak and Samarth Kulkarni. View Insider Buying and Selling for Crispr Therapeutics.

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Perigon Wealth Management LLC, Webster Bank N. A. and Farmers & Merchants Trust Co of Chambersburg PA. View Insider Buying and Selling for Crispr Therapeutics.

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRSP stock can currently be purchased for approximately $58.33.

Crispr Therapeutics has a market capitalization of $3.22 billion and generates $3.12 million in revenue each year. The company earns $-164,980,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.View Additional Information About Crispr Therapeutics.

The official website for Crispr Therapeutics is http://www.crisprtx.com/.

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]